$111 Million is the total value of Endurant Capital Management LP's 43 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 64.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRK | Sell | MERCK & CO INC | $4,569,333 | -19.7% | 44,384 | -10.0% | 4.10% | -17.4% |
| BSX | Sell | BOSTON SCIENTIFIC CORP | $2,528,750 | -23.3% | 47,893 | -21.5% | 2.27% | -21.1% |
| THC | Sell | TENET HEALTHCARE CORP | $1,788,979 | -62.1% | 27,151 | -53.2% | 1.61% | -61.0% |
| CI | Sell | THE CIGNA GROUP | $1,740,164 | -76.0% | 6,083 | -76.4% | 1.56% | -75.3% |
| OCUL | Sell | OCULAR THERAPEUTIX INC | $1,110,640 | -41.6% | 353,707 | -4.0% | 1.00% | -39.9% |
| IQV | Sell | IQVIA HLDGS INC | $776,376 | -82.0% | 3,946 | -79.4% | 0.70% | -81.5% |
| BLUE | Sell | BLUEBIRD BIO INC | $765,426 | -17.3% | 251,785 | -10.5% | 0.69% | -15.0% |
| SELB | Sell | SELECTA BIOSCIENCES INC | $480,513 | -37.5% | 453,314 | -33.9% | 0.43% | -35.6% |
| ADAP | Sell | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $243,316 | -68.0% | 311,944 | -62.0% | 0.22% | -67.0% |
| VKTX | Exit | VIKING THERAPEUTICS INC | $0 | – | -20,754 | -100.0% | -0.29% | – |
| BTAI | Exit | BIOXCEL THERAPEUTICS INCcall | $0 | – | -57,100 | -100.0% | -0.33% | – |
| MASI | Exit | MASIMO CORP | $0 | – | -2,850 | -100.0% | -0.41% | – |
| ACHC | Exit | ACADIA HEALTHCARE COMPANY IN | $0 | – | -9,153 | -100.0% | -0.64% | – |
| ZTS | Exit | ZOETIS INCcl a | $0 | – | -7,643 | -100.0% | -1.15% | – |
| TEVA | Exit | TEVA PHARMACEUTICAL INDS LTDcall | $0 | – | -175,000 | -100.0% | -1.15% | – |
| VTR | Exit | VENTAS INC | $0 | – | -41,575 | -100.0% | -1.72% | – |
| EHC | Exit | ENCOMPASS HEALTH CORP | $0 | – | -32,710 | -100.0% | -1.93% | – |
| MDT | Exit | MEDTRONIC PLC | $0 | – | -27,181 | -100.0% | -2.09% | – |
| QGEN | Exit | QIAGEN NV | $0 | – | -62,708 | -100.0% | -2.46% | – |
| CAH | Exit | CARDINAL HEALTH INC | $0 | – | -31,696 | -100.0% | -2.62% | – |
| BDX | Exit | BECTON DICKINSON & CO | $0 | – | -13,360 | -100.0% | -3.08% | – |
| A | Exit | AGILENT TECHNOLOGIES INC | $0 | – | -45,762 | -100.0% | -4.80% | – |
| LH | Exit | LABORATORY CORP AMER HLDGS | $0 | – | -32,569 | -100.0% | -6.86% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INCcall | $0 | – | -93,600 | -100.0% | -7.08% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -6,100 | -100.0% | -23.70% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LABORATORY CORP AMER HLDGS | 31 | Q2 2023 | 8.7% |
| ELEVANCE HEALTH INC | 29 | Q3 2023 | 8.8% |
| BECTON DICKINSON & CO | 28 | Q2 2023 | 9.8% |
| MCKESSON CORP | 27 | Q1 2023 | 4.4% |
| CENCORA INC | 26 | Q3 2023 | 5.9% |
| HOLOGIC INC | 24 | Q3 2023 | 7.5% |
| JOHNSON & JOHNSON | 24 | Q4 2021 | 5.5% |
| ZIMMER HLDGS INC | 23 | Q3 2023 | 7.5% |
| BOSTON SCIENTIFIC CORP | 22 | Q3 2023 | 5.5% |
| DAVITA INC | 22 | Q1 2021 | 4.9% |
View Endurant Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AZIYO BIOLOGICS, INC. | March 21, 2023 | 576,253 | 4.9% |
| Oxford Immunotec Global PLCSold out | February 17, 2021 | 0 | 0.0% |
View Endurant Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-10 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13D/A | 2023-09-08 |
| 13F-HR | 2023-08-14 |
| 3/A | 2023-05-24 |
| 13F-HR | 2023-05-15 |
| 3 | 2023-05-15 |
| SC 13D | 2023-05-15 |
| SC 13G/A | 2023-03-21 |
View Endurant Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.